Supercharged immune cells take on bile duct cancer in early trial
NCT ID NCT07614061
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new cell therapy for people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not responded to standard treatments. The therapy uses the patient's own immune T cells, enhanced with a protein called CD160 to better target cancer cells, given after a short chemotherapy course. The main goals are to check safety and find the right dose, with only 18 participants enrolled so far.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD160-enhanced autologous antigen-specific T cells (BTC-Ag-T, ACH-AgT001) plus lymphodepletion chemotherapy (cyclophosphamide and fludarabine)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced biliary tract cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome and low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Zhongshan Hospital, Fudan University
RECRUITINGShanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Can a targeted antibody boost chemotherapy for a rare bile duct cancer?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
- Immunotherapy-Chemo cocktail shows promise for Hard-to-Treat bile duct cancer